These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 31619848)

  • 21. Assessing the effects of long-term osteoporosis treatment by using conventional spine radiographs: results from a pilot study in a sub-cohort of a large randomized controlled trial.
    Dimai HP; Ljuhar R; Ljuhar D; Norman B; Nehrer S; Kurth A; Fahrleitner-Pammer A
    Skeletal Radiol; 2019 Jul; 48(7):1023-1032. PubMed ID: 30506302
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Three-year denosumab treatment in postmenopausal Japanese women and men with osteoporosis: results from a 1-year open-label extension of the Denosumab Fracture Intervention Randomized Placebo Controlled Trial (DIRECT).
    Sugimoto T; Matsumoto T; Hosoi T; Miki T; Gorai I; Yoshikawa H; Tanaka Y; Tanaka S; Fukunaga M; Sone T; Nakano T; Ito M; Matsui S; Yoneda T; Takami H; Watanabe K; Osakabe T; Okubo N; Shiraki M; Nakamura T
    Osteoporos Int; 2015 Feb; 26(2):765-74. PubMed ID: 25403903
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of denosumab treatment on bone mineral density and bone turnover markers in osteoporotic patients: real-life experience 2-year follow-up.
    Yazan CD; Bugdayci O; Ilgin C; Yavuz DG
    Arch Osteoporos; 2022 Sep; 17(1):125. PubMed ID: 36114901
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The clinical benefits of denosumab for prophylaxis of steroid-induced osteoporosis in patients with pulmonary disease.
    Ishiguro S; Ito K; Nakagawa S; Hataji O; Sudo A
    Arch Osteoporos; 2017 Dec; 12(1):44. PubMed ID: 28425086
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Denosumab: a cost-effective alternative for older men with osteoporosis from a Swedish payer perspective.
    Parthan A; Kruse M; Agodoa I; Silverman S; Orwoll E
    Bone; 2014 Feb; 59():105-13. PubMed ID: 24231131
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Changes in bone mineral density (BMD): a longitudinal study of osteoporosis patients in the real-world setting.
    Berry SD; Dufour AB; Travison TG; Zhu H; Yehoshua A; Barron R; Recknor C; Samelson EJ
    Arch Osteoporos; 2018 Nov; 13(1):124. PubMed ID: 30421141
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Follow-Up of Bone Mineral Density Changes in de novo Kidney Transplant Recipients Treated with Two Doses of the Receptor Activator of Nuclear Factor κB Ligand Inhibitor Denosumab.
    Kobel C; Frey D; Graf N; Wüthrich RP; Bonani M
    Kidney Blood Press Res; 2019; 44(5):1285-1293. PubMed ID: 31614356
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Denosumab treatment in postmenopausal women with osteoporosis does not interfere with fracture-healing: results from the FREEDOM trial.
    Adami S; Libanati C; Boonen S; Cummings SR; Ho PR; Wang A; Siris E; Lane J; ; Adachi JD; Bhandari M; de Gregorio L; Gilchrist N; Lyritis G; Möller G; Palacios S; Pavelka K; Heinrich R; Roux C; Uebelhart D
    J Bone Joint Surg Am; 2012 Dec; 94(23):2113-9. PubMed ID: 23097066
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Osteoporosis, bone mineral density and CKD-MBD: treatment considerations.
    Bover J; Bailone L; López-Báez V; Benito S; Ciceri P; Galassi A; Cozzolino M
    J Nephrol; 2017 Oct; 30(5):677-687. PubMed ID: 28432640
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Severe Rebound-Associated Vertebral Fractures After Denosumab Discontinuation: 9 Clinical Cases Report.
    Lamy O; Gonzalez-Rodriguez E; Stoll D; Hans D; Aubry-Rozier B
    J Clin Endocrinol Metab; 2017 Feb; 102(2):354-358. PubMed ID: 27732330
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Changes of Bone-Related Minerals during Denosumab Administration in Post-Menopausal Osteoporotic Patients.
    Suzuki T; Nakamura Y; Kato H
    Nutrients; 2017 Aug; 9(8):. PubMed ID: 28805705
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Protective Effect of Denosumab on Bone in Older Women with Primary Hyperparathyroidism.
    Eller-Vainicher C; Palmieri S; Cairoli E; Goggi G; Scillitani A; Arosio M; Falchetti A; Chiodini I
    J Am Geriatr Soc; 2018 Mar; 66(3):518-524. PubMed ID: 29364518
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Osteoporosis prevalence and characteristics of treated and untreated nursing home residents with osteoporosis.
    Zarowitz BJ; Cheng LI; Allen C; O'Shea T; Stolshek B
    J Am Med Dir Assoc; 2015 Apr; 16(4):341-8. PubMed ID: 25726417
    [TBL] [Abstract][Full Text] [Related]  

  • 34. New Frontiers in Osteoporosis Therapy.
    Cheng C; Wentworth K; Shoback DM
    Annu Rev Med; 2020 Jan; 71():277-288. PubMed ID: 31509477
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Denosumab or oral bisphosphonates in primary osteoporosis: a "real-life" study.
    Cairoli E; Palmieri S; Goggi G; Roggero L; Arosio M; Chiodini I; Eller-Vainicher C
    J Endocrinol Invest; 2018 Aug; 41(8):1005-1013. PubMed ID: 29340971
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Real-world Management of Women with Postmenopausal Osteoporosis Treated with Denosumab: A Prospective Observational Study in the Czech Republic and Slovakia.
    Růžičková O; Killinger Z; Kasalický P; Hamilton L; Tyl R; Tomková S; Kalouche-Khalil L
    Adv Ther; 2018 Oct; 35(10):1713-1728. PubMed ID: 30191465
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Assessment of Distal Radius Bone Mineral Density in Osteoporosis Patients Receiving Denosumab, Including Those with Rheumatoid Arthritis and Those Receiving Oral Glucocorticoids.
    Matsuno H
    Drugs R D; 2016 Dec; 16(4):347-353. PubMed ID: 27766589
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial.
    Leder BZ; Tsai JN; Uihlein AV; Wallace PM; Lee H; Neer RM; Burnett-Bowie SA
    Lancet; 2015 Sep; 386(9999):1147-55. PubMed ID: 26144908
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of denosumab on low bone mineral density in postmenopausal Japanese women receiving adjuvant aromatase inhibitors for non-metastatic breast cancer: 24-month results.
    Nakatsukasa K; Koyama H; Ouchi Y; Ono H; Sakaguchi K; Matsuda T; Kato M; Ishikawa T; Yamada K; Yoshimura M; Koizumi K; Sakurai T; Shigematsu H; Takahashi S; Taira S; Suzuki M; Narui K; Niikura N; Hasegawa Y; Miura D; Konishi E; Taguchi T;
    Breast Cancer; 2019 Jan; 26(1):106-112. PubMed ID: 30054855
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Using early biomarker data to predict long-term bone mineral density: application of semi-mechanistic bone cycle model on denosumab data.
    Zheng J; van Schaick E; Wu LS; Jacqmin P; Perez Ruixo JJ
    J Pharmacokinet Pharmacodyn; 2015 Aug; 42(4):333-47. PubMed ID: 26123919
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.